Recipharm in the news

Recipharm extends its manufacturing contract with BIAL for the Parkinson's drug Ongentys, which is now approved in several major markets including Japan.

Recipharm secures further funding from the Gates Foundation to advance AI-driven next-generation vaccine manufacturing.

Recipharm obtained funding to develop AI-driven tools to improve pharmaceutical manufacturing speed, cost, and efficiency.

Recipharm's Advanced Bio division secures Gates Foundation funding to advance AI and PAT technologies aimed at improving global medicine access.

Recipharm manufactured a protein-based pneumococcal vaccine for phase 2a trials led by ImmBIO and iiCON, targeting child mortality in low-income countries.

Recipharm launched new parenteral and sterility labs in Bengaluru to accelerate injectable drug development and testing.

Recipharm's Cuxhaven site is now a Centre of Excellence for advanced biologics analytics, enhancing in-house testing capabilities for ATMPs and biologics.

LGC opened a $72M chemical plant and Recipharm partnered with NeuroSense.

Recipharm partners in developing PrimeC, a combination drug to slow ALS progression using two existing anti-inflammatory medications.

Recipharm is adopting Veeva Vault quality management solutions to streamline and standardize its global pharmaceutical manufacturing quality operations.

Recipharm and OZ-UK partner to develop low global warming potential inhalers using sustainable propellants, accelerating the shift to greener pMDIs.

Ofichem acquired Recipharm's former Uppsala site to expand early-phase small molecule and emerging modality development capabilities.

University of Oxford and ReciBioPharm are expanding their collaboration to develop and scale up production of malaria vaccines for clinical trials.

Recipharm is expanding its manufacturing role for Oxford's malaria vaccine candidates amid ongoing clinical trials and business restructuring.

Recipharm's biopharmaceutical division will produce two malaria vaccine candidates for Oxford University's clinical trials.

Recipharm and ProductLife Group have partnered to streamline pharmaceutical development and regulatory processes, speeding up clinical trials and market access.

The Veeva R&D and Quality Summit Europe will showcase how AI and connected platforms are advancing pharmaceutical development and manufacturing with keynotes from major biopharma companies including Recipharm.

Recipharm expanded its global pharmaceutical CDMO operations by acquiring Kemwell's businesses in Sweden, the US, and India for 1.7 billion SEK, enhancing its market presence and manufacturing capabilities.

The report analyzes the global Pharmaceutical Contract Filling Services market through 2032, detailing key players, market segments, regional trends, and COVID-19 impacts to guide business decisions.